Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | ACSS2 | Q9NR19 | 6/20 | 0.35 |
| ▸ | PDE2A | O00408 | 7/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | PLG | P00747 | 2/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7072446 | 0.90 | LMNA (0.41) | TP53ACSS2 | |
| SCHEMBL7122845 | 0.88 | GRN (0.37) | PLG | |
| SCHEMBL7075194 | 0.86 | ACSS2 (0.36) | TP53ACSS2MAPT | |
| SCHEMBL7074567 | 0.86 | TAS1R3 (0.38) | PLG | |
| SCHEMBL7068659 | 0.84 | NPC1 (0.36) | ACSS2 | |
| SCHEMBL7071905 | 0.83 | TPSAB1 (0.33) | ACSS2MAPT | |
| SCHEMBL7069828 | 0.82 | TPSAB1 (0.37) | PDE2APLG | |
| SCHEMBL7067706 | 0.81 | TPSAB1 (0.34) | ACSS2 | |
| SCHEMBL7069832 | 0.81 | TPSAB1 (0.34) | — | |
| SCHEMBL7069756 | 0.81 | TPSAB1 (0.34) | ACSS2PDE2APDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030212120-A1 | Compositions comprising a substituted benzimidazole useful for treating immunomediated inflammatory disorders | AXYS PHARMACEUTICALS, INC. (US) | 2003-11-13 | — | — | US | disclosed |
| US-6562854-B2 | Antiinflammatory agents; respiratory system disorders | AXYS PHARMACEUTICALS, INC. | 2003-05-13 | — | — | US | disclosed |
| US-20010053779-A1 | Novel compounds and compositions for treating diseases asociated with protease activity | Celera Corporation | 2001-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010053779-A1 | Novel compounds and compositions for treating diseases asociated with protease activity | CMA1, CPA3, TPSG1 | TP53 3162/4885ACSS2 609/4885PDE2A 1059/4885 |
| US-20030212120-A1 | Compositions comprising a substituted benzimidazole useful for treating immunomediated inflammatory disorders | CMA1, TPSG1, TPSD1 | TP53 2387/4885ACSS2 746/4885PDE2A 2326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.